Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 1

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 1
---
 improvement of ~271%, almost tripling 2023.                          |

| · | Free                                                                                  
 Cash Flow2 expanded to EUR 335 million in Q4 primarily driven by improved working     
 capital management across the supply chain. FCF for the FY24 reached EUR 266 million. |

| · | Leverage                                                                                     
 ratio3 declined to 4.6x (4.5x at cc), driven by EBITDA improvement, the €1.6                 
 billion cash inflow from the SRAAS divestment completed in June, and improved free cash flow 
 generation.                                                                                  |

| · | Strengthened                                                 
 balance sheet, while liquidity advanced to EUR 1.9 billion4. |

| · | Achieved                                                                                   
 all innovation milestones set for 2024, noteworthy the regulatory approval submissions for 
 Fibrinogen in the EU and U.S.                                                              |

Barcelona, Spain – February 26, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines,
reported record results for the full year, with accelerated sequential improvement across key metrics, culminating in a strong fourth
quarter.

Nacho Abia, Chief Executive Officer, commented,
“Grifols delivered an all-time high performance, achieving its 2024 commitments and goals thanks to the team's unwavering focus
and dedication during what was a challenging year. Their hard work and dedication to patients are apparent across the company, from a
re-energized Biopharma business to completing innovation milestones, to the strategic alliance with Haier Group in support of deleveraging.
Our actions have built clear momentum and position us for sustainable, profitable growth into 2025 and beyond.”

Rahul Srinivasan, Chief Financial Officer,
said, “Grifols delivered a strong finish to cap off our second consecutive record year, a testament to the commitment and drive
of our Grifols’ team. With significant progress in de-risking our balance sheet and a strong focus on free cash flow generation
following our 2024 outperformance, we have a clear opportunity to drive a substantial re-rating of our story over time.”

Note: For comparative purposes with FY 2024, the financial statements for Q3'23 and Q4’23 have been re-expressed according to the Inside Information released on July 30, 2024, and further disclosed in accordance with Note